	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE RMATION DISCLOSURE EMENT BY APPLICANT	ATTY. DOCKET NO. 1038-971 MIS:bh	SERIAL NO CENTRAL NO C
	0/8	APPLICANT Andrew D. Murdin et	al TECH GENTER 1600/29
Signal of the state of the stat	The state of	FILING DATE September 7, 1999	GROUP 1643
	T.S. PAT	ENT DOCUMENTS	,

## U.S. PATENT DOCUMENTS

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
GUL	4,245,050		Na Kanishi etal.	435	191	
1	5,015,580		Christon etal.	800	267	
ļ .	5,151,264		Samain etal	424	1,21	
4ve	5,075,109		Tile et al.	424	1931	
				ļ		
	·					

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUN	TRY	CLASS	SUBCL.	TRANS	LATION
gil		WO 98/02546		WI	P 0			YES	NO
i		WO 93/24640		WIF	<del>&gt;</del> U				
		WO 94/27435		WIF	ט ?				
		WO 91/06282		WIP	V				
,		WO 95/34308		WIP	0				
qu		WO 94/24263		WIP	V				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
SVC	1	Grayston et al. (1995), Journal of Infectious Diseases 168:1231-1235							
Ì	2	Campos et al. (1995), Investigation of Ophthalmology and Visual Science 36:1477-1491							
	3	Grayston et a	al (1990),	Journal of	Infect	ious Dis	eases 1	61:618-6	525
	4	Marrie (1993), Clinical Infectious Diseases. 18:501-515							
	5	Wang et al (1986), Chlamydial infections. Cambridge University Press, Cambridge. p. 329-333							
5VL	6	Normann et al (1998), Acta Paediatrica, 87:23-27							
EXAMINER: Shin-Lin Chln Date Considered: 6-1-24									

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  APPLICANT Andrew D. Murdin et al  FILING DATE September 7, 1999 1643	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-971 MIS:bh	SERIAL NO. 09/391,606
Andrew D. Murdin et al FILING DATE GROUP			
FILING DATE GROUP	( )		t al
	ATENTS TO	FILING DATE September 7, 1999	

0'	THER	DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
5rc	7	Saikku et al.(1988), Lancet 983-985	
<del></del>	8	Thom et al. (1992), JAMA 268:68-72	
	9	Linnanmaki et al. (1993), Circulation 87:1130-1134	
	10	Saikku et al. (1992), Annals Internal Medicine 116:273-278	
	11	Melnick et al(1993), American Journal of Medicine 95:499-504	
	12	Shor et al. (1992), South African. Medical Journal 82:158-161	
	13	Kuo et al. (1993), Journal of Infectious Diseases 167:841-849	
	14	Kuo et al. (1993), Arteriosclerosis and Thrombosis 13:1501-1504	
	15	Campbell et al (1995), Journal of Infectious Diseases 172:585-588	
	16	Chiu et al. Circulation, 1997, Oct.7; 96(7);2144-2148	
	17	Ramirez et al (1996) Annals of Internal Medicine 125:979-982	
	18	Jackson et al. Abst. K121, p272, 36th ICAAC, 15-18 Sept. 1996, New Orleans	
	19	Fong et al (1997) Journal of Clinical Microbiolology 35:48-52	
	20	Hahn DL, et al. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. Ann Allergy Asthma Immunol. 1998 Jan; 80(1): 45-49.	
·	21	Hahn DL, et al. Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma. Epidemiol Infect. 1996 Dec; 117(3): 513-517.	
	22	Bjornsson E, et al. Serology of chlamydia in relation to asthma and bronchial hyperresponsiveness. Scand J Infect Dis. 1996; 28(1): 63-69	
	23	Hahn DL. Treatment of <i>Chlamydia pneumoniae</i> infection in adult asthma: a before-after trial. J Fam Pract. 1995 Oct; 41(4): 345-351	
	24	Allegra L, et al. Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection. Eur Respir J. 1994 Dec; 7(12): 2165-2168	
GN	25	Hahn DL, et al. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA. 1991 Jul 10; 266(2): 225-230	
EXAMINER:	5	hin-Lin Weln DATE CONSIDERED: 61-04	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

Sheet <u>3</u> of <u>3</u>

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-971 MIS:bh	SERIAL NO. 09/391,606
	NFORMATION DISCLOSURE TATEMENT BY APPLICANT		
	The Res	APPLICANT Andrew D. Murdin e	t al
	THAT IS NOT THE STATE OF THE ST	FILING DATE September 7, 1999	GROUP 1643
L	Monary 1		

	OFFICE L
THER	DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
26	Pal et al. (1996) Infection and Immunity.64:5341
27	Jones et al. (1995) Vaccine 13:715-723
28	Igietsemes et al. (1993) Immunology 5:317 (Duplicate See #29 below)
29	Igietseme et al (1993) Regional Immunology 5:317-324
30	Magee et al (1993) Regional Immunology 5: 305-311
31	Landers et al (1991) Infection & Immunity 59:3774-3777
32	Magee et al (1995) Infection & Immunity 63:516-521
33	Cotter et al. (1995) Infection and Immunity 63:4704-4714
34	Campbell et al (1990) Infection and Immunity 58:93-97
35	McCafferty et al (1995) Infection and Immunity 63:2387-2389
36	Knudsen et al (1996)Third Meeting of the European Society for Chlamydia Research, Vienna
37	Wiedmann-Al-Ahmad M, et al. Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of Chlamydia pneumoniae. Clin Diagn Lab Immunol. 1997 Nov; 4(6): 700-704
38	Xiang, 1995, Immunity 2: 129-35
39	Tang et al, Nature 1992; 356:152-154
40	Davis et al., Vaccine 1994, 12:1503-1509
41	Yang et al, 1993, Infection & Immunity, vol. 61, pp 2037-40
42	Chi E.Y., Kuo C.C., Grayston J.T. 1987. Unique ultrastructure in the elementary body of Chlamydia sp strain TWAR. J. Bacteriol 169(8): 3757-63
41	11/1-Lin When DATE CONSIDERED: 6-1-04
	26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.